These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9123684)

  • 1. [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients].
    Schöps W; Prior V; Golka K; Blaszkewicz M; Cascorbi I; Roots I; Bolt HM; Kierfeld G
    Urologe A; 1997 Jan; 36(1):64-7. PubMed ID: 9123684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany.
    Golka K; Prior V; Blaszkewicz M; Cascorbi I; Schöps W; Kierfeld G; Roots I; Bolt HM
    Scand J Work Environ Health; 1996 Oct; 22(5):332-8. PubMed ID: 8923605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylation phenotypes and bladder cancer.
    Hanke J; Krajewska B
    J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylator phenotype in human bladder cancer.
    Miller ME; Cosgriff JM
    J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetyltransferase 2 phenotype in painters with bladder cancer and controls.
    Golka K; Weistenhofer W; Jedrusik P; Geller F; Blaszkewicz M; Bolt HM
    Ann Acad Med Singap; 2001 Sep; 30(5):464-7. PubMed ID: 11603126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
    Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
    Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
    Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
    Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
    Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
    Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
    Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
    Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.
    Pink JC; Messing EM; Reznikoff CA; Bryan GT; Swaminathan S
    Drug Metab Dispos; 1992; 20(4):559-65. PubMed ID: 1356735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interdisciplinary networking for clinical and molecular questions in non-muscle invasive urothelial carcinoma of the bladder].
    Denzinger S; Hartmann A; Hofstaedter F; Knuechel R; Wild PJ; Zaak D; Stief C; Wieland WF; Stoehr R; Burger M
    Urologe A; 2007 Sep; 46(9):1126-8. PubMed ID: 17634910
    [No Abstract]   [Full Text] [Related]  

  • 14. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
    Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
    Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
    Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
    Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine acetylator phenotyping during maturation in infants.
    Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
    Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.